Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Hormone Receptor Positive HER-2 Negative Breast Cancer|Advanced or Metastatic Breast Cancer|BRCA1 Mutation|BRCA2 Mutation|PALB2 Gene Mutation
Interventions: DRUG: Niraparib + Elacestrant|DRUG: Niraparib
Sponsor: German Breast Group
Collaborators: Stemline Therapeutics, Inc.|GlaxoSmithKline